Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin for Early-Stage Indolent Lymphomas
NCT00493467Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2006
- Primary completion
- Apr 2015
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ibritumomab tiuxetan in lymphoma, sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2006; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT00493467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00493467.